Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14332118 | 0.84 | CYP3A4 (0.43) | CES2CES1NPC1RAB9AALDH1A1 | |
| SCHEMBL14330649 | 0.79 | CYP11B2 (0.38) | CES2CES1NPC1RAB9AP2RX7 | |
| SCHEMBL17120565 | 0.78 | CES2 (0.42) | CES2CES1NPC1RAB9AKDM4E | |
| SCHEMBL18664023 | 0.78 | CES2 (0.42) | CES2CES1NPC1RAB9AKDM4E | |
| SCHEMBL30352878 | 0.78 | CES2 (0.42) | CES2CES1KDM4EALDH1A1TDP1 | |
| SCHEMBL2554655 | 0.78 | CES2 (0.42) | CES2CES1KDM4EALDH1A1TDP1 | |
| SCHEMBL18661269 | 0.78 | CES2 (0.42) | CES2CES1NPC1RAB9AKDM4E | |
| SCHEMBL14332048 | 0.78 | CES2 (0.42) | CES2CES1NPC1RAB9AP2RX7 | |
| SCHEMBL14405706 | 0.75 | CES2 (0.40) | CES2CES1P2RX7KDM4ETDP1 | |
| SCHEMBL11913027 | 0.75 | CES2 (0.40) | CES2CES1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919874-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2021-02-16 | — | — | US | disclosed |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2019-12-19 | — | — | US | disclosed |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2019-08-06 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| EP-3351541-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2788343-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (NC) INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2723731-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8883797-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883797-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012177728-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177725-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GAA, GPX1 | CES2 240/4885CES1 152/4885NPC1 458/4885 |
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885NPC1 565/4885 |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | MMEL1, GAA, GPX1 | CES2 240/4885CES1 152/4885NPC1 458/4885 |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885NPC1 565/4885 |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885NPC1 565/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885NPC1 565/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885NPC1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.